Peptide Phage Display as a Tool for Drug Discovery: Targeting Membrane Receptors

被引:146
作者
Molek, Peter [1 ]
Strukelj, Borut [1 ,2 ]
Bratkovic, Tomaz [1 ]
机构
[1] Univ Ljubljana, Fac Pharm, Dept Pharmaceut Biol, SI-1000 Ljubljana, Slovenia
[2] Jozef Stefan Inst, Dept Biotechnol, SI-1000 Ljubljana, Slovenia
关键词
membrane receptors; agonists; antagonists; peptides; phage display; LIFE IN-VIVO; GROWTH-FACTOR; AFFINITY TAGS; ERYTHROPOIETIN-RECEPTOR; MOLECULAR RECOGNITION; BINDING PEPTIDES; HOMING PEPTIDE; CLINICAL-APPLICATIONS; THERAPEUTIC PEPTIDES; KINASE INHIBITORS;
D O I
10.3390/molecules16010857
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Ligands selected from phage-displayed random peptide libraries tend to be directed to biologically relevant sites on the surface of the target protein. Consequently, peptides derived from library screenings often modulate the target protein's activity in vitro and in vivo and can be used as lead compounds in drug design and as alternatives to antibodies for target validation in both genomics and drug discovery. This review discusses the use of phage display to identify membrane receptor modulators with agonistic or antagonistic activities. Because isolating or producing recombinant membrane proteins for use as target molecules in library screening is often impossible, innovative selection strategies such as panning against whole cells or tissues, recombinant receptor ectodomains, or neutralizing antibodies to endogenous binding partners were devised. Prominent examples from a two-decade history of peptide phage display will be presented, focusing on the design of affinity selection experiments, methods for improving the initial hits, and applications of the identified peptides.
引用
收藏
页码:857 / 887
页数:31
相关论文
共 147 条
[1]   Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model [J].
Arap, W ;
Pasqualini, R ;
Ruoslahti, E .
SCIENCE, 1998, 279 (5349) :377-380
[2]   Steps toward mapping the human vasculature by phage display [J].
Arap, W ;
Kolonin, MG ;
Trepel, M ;
Lahdenranta, J ;
Cardó-Vila, M ;
Giordano, RJ ;
Mintz, PJ ;
Ardelt, PU ;
Yao, VJ ;
Vidal, CI ;
Chen, L ;
Flamm, A ;
Valtanen, H ;
Weavind, LM ;
Hicks, ME ;
Pollock, RE ;
Botz, GH ;
Bucana, CD ;
Koivunen, E ;
Cahill, D ;
Troncoso, P ;
Baggerly, KA ;
Pentz, RD ;
Do, KA ;
Logothetis, CJ ;
Pasqualini, R .
NATURE MEDICINE, 2002, 8 (02) :121-127
[3]   Computational analysis of membrane proteins: the largest class of drug targets [J].
Arinaminpathy, Yalini ;
Khurana, Ekta ;
Engelman, Donald M. ;
Gerstein, Mark B. .
DRUG DISCOVERY TODAY, 2009, 14 (23-24) :1130-1135
[4]   Phage display technology: clinical applications and recent innovations [J].
Azzazy, HME ;
Highsmith, WE .
CLINICAL BIOCHEMISTRY, 2002, 35 (06) :425-445
[5]   Neuropilins in Tumor Biology [J].
Bagri, Anil ;
Tessier-Lavigne, Marc ;
Watts, Ryan J. .
CLINICAL CANCER RESEARCH, 2009, 15 (06) :1860-1864
[6]   Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors [J].
Bantscheff, Marcus ;
Eberhard, Dirk ;
Abraham, Yann ;
Bastuck, Sonja ;
Boesche, Markus ;
Hobson, Scott ;
Mathieson, Toby ;
Perrin, Jessica ;
Raida, Manfred ;
Rau, Christina ;
Reader, Valerie ;
Sweetman, Gavain ;
Bauer, Andreas ;
Bouwmeester, Tewis ;
Hopf, Carsten ;
Kruse, Ulrich ;
Neubauer, Gitte ;
Ramsden, Nigel ;
Rick, Jens ;
Kuster, Bernhard ;
Drewes, Gerard .
NATURE BIOTECHNOLOGY, 2007, 25 (09) :1035-1044
[7]   Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis [J].
Binétruy-Tournaire, R ;
Demangel, C ;
Malavaud, B ;
Vassy, R ;
Rouyre, S ;
Kraemer, M ;
Plouët, J ;
Derbin, C ;
Perret, G ;
Mazie, JC .
EMBO JOURNAL, 2000, 19 (07) :1525-1533
[8]   Isolation and characterization of antagonist and agonist peptides to the human melanocortin 1 receptor [J].
Bonetto, S ;
Carlavan, I ;
Baty, D .
PEPTIDES, 2005, 26 (11) :2302-2313
[9]   Progress in phage display: evolution of the technique and its applications [J].
Bratkovic, Tomaz .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2010, 67 (05) :749-767
[10]   Peptidic Tumor Targeting Agents: The Road from Phage Display Peptide Selections to Clinical Applications [J].
Brown, Kathlynn C. .
CURRENT PHARMACEUTICAL DESIGN, 2010, 16 (09) :1040-1054